We presented our results regarding new possible drugs (small molecule leads) to fight Alzheimer’s Disease at a recent meeting at Stanford, supported by the NIH Roadmap Nanomedicine center and NIH grants. We may have multiple small molecules which appear to inhibit toxicity of Abeta, the protein which is the toxic element in Alzheimer’s Disease. Considering all the technology development that had to be done in the first five years, these results have come very quickly (in the last 3 years), which is exciting. We are now looking to apply these methods to other protein misfolding diseases (we have pilot projects for Huntington’s Disease underway).
